Compare Citius Pharmaceuticals Inc (CTXR) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Petróleo Brasileiro SA — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Petróleo Brasileiro SA trades at $24.9 (market cap $151.94B). The key difference: Petróleo Brasileiro SA is far larger — about 11155.7× Citius Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Petróleo Brasileiro SA for 25 Days on average.
| CTXR | PBR | |
|---|---|---|
Market Cap | $13.62M | $151.94B |
Volume | 132,438 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $1.82 | $24.69 |
52-Week Low | $0.48 | $11.54 |
Typical Hold Time | 16 Days | 25 Days |
Enterprise Value | $3.79M | $212.36B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Petrobras (PBR) trades at $23.99, up 0.8% today, with a bullish technical signal from moving averages and strong fundamental metrics including a P/E of 6.24 and net income margin of 24.52%. Recent news highlights a new oil discovery off Amapa and the deployment of the P-80 platform, supporting production growth. Cash flow from operations remains robust at $36.05 billion for 2025, though 2026 projections show a net cash outflow.
The outlook is positive given low valuations, high profitability, and strategic expansions, but risks include volatile oil prices and political influence in Brazil. Analysts are generally bullish with a 50% buy rating and a consensus price target of $22.33, slightly below the current price, indicating potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
